Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 728 of 5804
-
New antibody cocktail takes on tough ovarian cancers
Disease control Recruiting nowThis study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (also known as REGN4018), with or without…
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New ultrasound technique may predict chemo success early in breast cancer
Diagnosis OngoingThis phase II/III trial studies if contrast-enhanced ultrasounds using a contrast dye, perflutren lipid microspheres (Definity), can predict the response to chemotherapy by estimating the pressure in the cancer in patients with breast cancer that has spread to nearby tissues and …
Phase: PHASE2, PHASE3 • Sponsor: Kibo Nam • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug shows promise for rare genetic syndrome in toddlers
Disease control OngoingThis study will investigate the effect of treatment with tiratricol (also called Triac) in young boys (≤30 months) with MCT8 deficiency (also called the Allan-Herndon-Dudley syndrome (AHDS)). The hypothesis tested is that treatment with tiratricol will have a beneficial effect on…
Phase: PHASE2 • Sponsor: Rare Thyroid Therapeutics International AB • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Engineered immune cells take on childhood brain cancer
Disease control Recruiting nowThis phase I trial investigates the side effects of chemotherapy and cellular immunotherapy in treating children with IL13Ralpha2 positive brain tumors that have come back after a period of improvement (recurrent) or do not respond to treatment (refractory). Cellular immunotherap…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug aims to stop Flare-Ups in rare autoimmune disease
Disease control OngoingThis study aims to evaluate the efficacy and safety of inebilizumab for the prevention of flare of Immunoglobulin G4-related disease (IgG4-RD).
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug combo shows promise for tough lung cancer
Disease control OngoingThis phase II trial studies the effects of durvalumab and lurbinectedin in treating patients with extensive stage small cell lung cancer that has come back (relapsed) or has not responded to previous treatment with chemotherapy and immunotherapy (refractory). Monoclonal antibodie…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Could a stronger dose of ocrevus slow MS disability better?
Disease control OngoingThis is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with PPMS, in comparison to the approved 600 milligrams (mg) d…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Promising combo targets CLL in untreated patients
Disease control OngoingThis study will help researchers collect more information about how effective the combination of venetoclax and obinutuzumab is in treating CLL in people who have not received a previous treatment for their cancer.
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Weekly shot could replace daily hormone injections for growth hormone deficiency
Disease control CompletedA 38-week dosing trial of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus placebo-control. A daily somatropin product arm is also included to assist clinical judgement on the trial results. A total of 264 adults (males and females) with gr…
Phase: PHASE3 • Sponsor: Ascendis Pharma Endocrinology Division A/S • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New combo therapy aims to boost CAR T-Cell power against lymphoma
Disease control OngoingThis phase I/II trial studies the safety of acalabrutinib and axicabtagene ciloleucel in treating patients with B-cell lymphoma. Acalabrutinib may stop the growth of tumor cells by blocking key pathways needed for cell growth. Immunotherapy with axicabtagene ciloleucel is enginee…
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Metabolic MRI could spot prostate cancer without a needle
Diagnosis TerminatedThis is a two-tiered pilot study in which there will be no randomization and no placebo treatment. This study will be to perform metabolic magnetic resonance imaging on men suspected to have a prostate cancer to understand if metabolic MRI can be safely performed on this populati…
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
Could a Copper-Binding drug shrink thickened heart muscle?
Disease control CompletedThis research study has been designed to test whether a drug called trientine dihydrochloride (also called Cufence) reduces heart muscle thickening, improves exercise capacity, improves heart function and reduces abnormal heart rhythms in patients with hypertrophic cardiomyopathy…
Phase: PHASE2 • Sponsor: Manchester University NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Smarter radiation aims to outsmart pancreatic cancer
Disease control CompletedThe purpose of this study is to compare the efficacy and safety of a recurrence-pattern-based-volume versus conventional-volume stereotactic body radiation therapy for locally advanced pancreatic cancer, so as to determine whether the target delineation method based on recurrence…
Phase: NA • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New pill could cut dangerous lung Flare-Ups in bronchiectasis patients
Disease control CompletedThe primary objective of this study is to evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period.
Phase: PHASE3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New device plugs dangerous heart valve leaks without open surgery
Disease control OngoingThe Paradigm study is a prospective, multicenter, single arm study to demonstrate the safety and effectiveness of the Amplatzer Valvular Plug III (AVP III) as a treatment for clinically significant PVLs following surgical implant of a mechanical or biological heart valve implante…
Phase: NA • Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New hope for rare blood vessel disorder: targeted drug shows promise
Disease control CompletedArteriovenous malformation (AVM) is a congenital vascular anomaly that progresses throughout life and causes complications including tissue destruction due to rapid overgrowth, bleeding, functional deficits, severe deformity and cardiac failure. Unfortunately, traditional managem…
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo shows promise for Tough-to-Treat breast cancer
Disease control CompletedThis trial studies how well the drug tucatinib works when given with trastuzumab deruxtecan (T-DXd). It will also look at what side effects happen when these drugs are given together. A side effect is anything a drug does besides treating cancer. Participants in this trial have …
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New ablation technique aims to zap heart flutter with less radiation and greater precision
Disease control Recruiting nowCatheter ablation of the cavo-tricuspid isthmus (CTI) is the curative first-line therapy for typical atrial flutter. Currently, two approaches are used in clinical practice. In contrast to the conventional linear ablation approach, the Maximum voltage-guided (MVG) strategy aims t…
Phase: NA • Sponsor: Klinikum-Fuerth • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New monthly shot shows promise for Tough-to-Treat gout
Disease control CompletedThis is one of two replicate randomized, double-blind, placebo-controlled, parallel arm trials to determine the safety and efficacy of two different dose levels of SEL-212 compared to placebo. 112 and 153 patients, stratified as to the presence or absence of tophi, were randomize…
Phase: PHASE3 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for advanced breast cancer: giredestrant trial shows promise
Disease control OngoingThis Phase II, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant compared with physician's choice of endocrine monotherapy in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative …
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC